Literature DB >> 20538734

Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.

Doriane A Gouas1, Hong Shi, Agnès H Hautefeuille, Sandra L Ortiz-Cuaran, Pénélope C Legros, Katarzyna J Szymanska, Olivier Galy, Lars A Egevad, Behnoush Abedi-Ardekani, Klas G Wiman, Olivier Hantz, Claude Caron de Fromentel, Isabelle A Chemin, Pierre L Hainaut.   

Abstract

Aflatoxin B(1) (AFB(1)) is a risk factor for hepatocellular carcinoma (HCC) in many low-resource countries. Although its metabolites bind at several positions in TP53, a mutation at codon 249 (AGG to AGT, arginine to serine, p.R249S) accounts for 90% of TP53 mutations in AFB(1)-related HCC. This specificity suggests that p.R249S confers a selective advantage during hepatocarcinogenesis. Using HCC cell lines, we show that p.R249S has lost the capacity to bind to p53 response elements and to transactivate p53 target genes. In p53-null Hep3B cells, stable transfection of p.R249S or of another mutant, p.R248Q, did not induce significant changes in cell proliferation and survival after cytotoxic stress. In contrast, in a cell line that constitutively expresses both p.R249S and the hepatitis B virus antigen HBx (PLC/PRF/5), silencing of either p.R249S or HBx by RNA interference slowed down proliferation, with no additive effects when both factors were silenced. Furthermore, the two proteins appear to form a complex. In human HCC samples, mutation at codon 249 did not correlate with p.R249S protein accumulation or HBx truncation status. We suggest that p.R249S may contribute to hepatocarcinogenesis through interaction with HBx, conferring a subtle growth advantage at early steps of the transformation process, but that this interaction is not required for progression to advanced HCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538734     DOI: 10.1093/carcin/bgq118

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  18 in total

1.  Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.

Authors:  Jingjing Jiao; Weibo Niu; Ying Wang; Keith Baggerly; Yuanqing Ye; Xifeng Wu; Dewitt Davenport; Jose Luis Almeda; Monica M Betancourt-Garcia; R Armour Forse; Heather L Stevenson; Gordon P Watt; Joseph B McCormick; Susan P Fisher-Hoch; Laura Beretta
Journal:  Cancer Prev Res (Phila)       Date:  2017-10-31

2.  Association of Aflatoxin and Gallbladder Cancer.

Authors:  Jill Koshiol; Yu-Tang Gao; Michael Dean; Patricia Egner; Chirag Nepal; Kristine Jones; Bingsheng Wang; Asif Rashid; Wen Luo; Alison L Van Dyke; Catterina Ferreccio; Michael Malasky; Ming-Chang Shen; Bin Zhu; Jesper B Andersen; Allan Hildesheim; Ann W Hsing; John Groopman
Journal:  Gastroenterology       Date:  2017-04-17       Impact factor: 22.682

3.  Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.

Authors:  Peng Liao; Shelya X Zeng; Xiang Zhou; Tianjian Chen; Fen Zhou; Bo Cao; Ji Hoon Jung; Giannino Del Sal; Shiwen Luo; Hua Lu
Journal:  Mol Cell       Date:  2017-12-07       Impact factor: 17.970

4.  The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma.

Authors:  Yan An; Yanfang Guan; Yaping Xu; Yingxin Han; Chi Wu; Chaohui Bao; Boping Zhou; Haiyan Wang; Mingxia Zhang; Weilong Liu; Lin Qiu; Zeguang Han; Yongsheng Chen; Xuefeng Xia; Jiayin Wang; Zhentian Liu; Wanqiu Huang; Xin Yi; Jian Huang
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

5.  TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.

Authors:  Doriane A Gouas; Stphanie Villar; Sandra Ortiz-Cuaran; Pénélope Legros; Gilles Ferro; Gregory D Kirk; Olufunmilayo A Lesi; Maimuna Mendy; Ebrima Bah; Marlin D Friesen; John Groopman; Isabelle Chemin; Pierre Hainaut
Journal:  Carcinogenesis       Date:  2012-06       Impact factor: 4.944

Review 6.  MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled.

Authors:  Catherine M Greene; Robert B Varley; Matthew W Lawless
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

7.  Hepatocellular carcinoma: focus on different aspects of management.

Authors:  Sene Waly Raphael; Zhang Yangde; Chen Yuxiang
Journal:  ISRN Oncol       Date:  2012-05-13

8.  The p53R172H mutant does not enhance hepatocellular carcinoma development and progression.

Authors:  Leanne G Ahronian; David R Driscoll; David S Klimstra; Brian C Lewis
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

9.  Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

Authors:  Fatou Traoré; Emmanuelle Gormally; Stéphanie Villar; Marlin D Friesen; John D Groopman; Guy Vernet; Souleymane Diallo; Pierre Hainaut; Moussa Y Maiga
Journal:  BMC Infect Dis       Date:  2015-04-11       Impact factor: 3.090

10.  Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish.

Authors:  Jeng-Wei Lu; Wan-Yu Yang; Su-Mei Tsai; Yueh-Min Lin; Pen-Heng Chang; Jim-Ray Chen; Horng-Dar Wang; Jen-Leih Wu; Shiow-Lian Catherine Jin; Chiou-Hwa Yuh
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.